A Food and Drug Administration advisory committee on Friday recommended allowing two more unproven peptides to be compounded, capping a two-day meeting that raised questions about whether the agency was weakening the guardrails designed to keep untested drugs from reaching patients.
FOR SUBSCRIBERSTrump’s final campaign swing is taking on a darker tone
FOR SUBSCRIBERSMel Robbins has midterms advice for you
FOR SUBSCRIBERSTrump’s final campaign swing is taking on a darker tone
FOR SUBSCRIBERSMel Robbins has midterms advice for you
Just a moment.
We are getting your experience ready.















